Background. Increasing numbers of children perinatally infected with human immunodeficiency virus (HIV) are reaching adolescence, largely because of advances in treatment over the past 10 years, but little is known about their current health status. We describe here the living conditions and clinical and immunovirologic outcomes at last evaluation among this pioneering generation of adolescents who were born before the introduction of prophylaxis for vertical transmission and whose infections were diagnosed at a time when treatment options were limited.
and their changes over time have been described for children with a median age of up to 10-12 years [1, 2] . Some studies have reported that highly active ART (HAART) is effective at decreasing mortality and morbidity in the pediatric population [3] [4] [5] [6] [7] . Other studies have described the immunovirologic impact of HAART [7] [8] [9] and factors predictive of the quality of immune reconstitution [10, 11] . Most surveys have included children identified on the basis of clinical symptoms as well as children followed up prospectively since birth, with no focus on the adolescent subpopulation [12] .
The French Perinatal Cohort (EPF) has included mother-child pairs since 1985 and has followed up infected children from birth to the age of 18 years, providing a unique opportunity to describe long-term clinical, immunologic, and virologic outcomes among adoDownloaded from https://academic.oup.com/cid/article-abstract/51/2/214/303546 by guest on 14 May 2018 lescents perinatally infected with HIV. This first generation of adolescents born before the introduction of methods for preventing mother-to-child transmission has experienced an increase in the availability of antiretroviral drugs during their lifetime, from zidovudine monotherapy in 1987 to various treatment combinations commonly referred to as HAART since 1996. We report here the long-term clinical outcomes and living conditions among this unique pioneering generation.
METHODS

The Agence Nationale de Recherche sur le SIDA et les Hé-patites Virales (ANRS) EPF (EPF/ANRS CO10).
The EPF is a national prospective multicenter cohort that was initiated in 1985. HIV-1-infected pregnant women and their children have been included at 90 health care centers throughout France. An infant is considered to be infected if HIV-1 is detected by virologic tests in 2 separate samples, if anti-HIV-1 antibodies persist after 18 months of age, or if the subject died of AIDSrelated causes before the age of 18 months in the absence of virus isolation. Clinical and biological data have been collected for HIV-infected children via completion of standardized questionnaires at 6-month intervals, as described elsewhere [13] . Questionnaires were not completed after the age of legal majority (18 years) . No specific recommendations for obstetric care or HIV treatment were made for women and children enrolled, although investigators were encouraged to follow national treatment guidelines as regularly published and updated [14] [15] [16] .
This cohort study was approved, in accordance with French law, by the Cochin Hospital Institutional Review Board and the French national data protection agency (Commission Nationale de l'Informatique et des Libertés).
Study population. All HIV-1-infected children born to mothers included in the EPF between 1985 and 31 December 1993 were eligible for this study. This population was not exposed to perinatal prophylaxis for mother-to-child transmission, because such prophylaxis was not available before April 1994. Of the 2202 exposed children, 348 were infected with HIV-1.
Study variables. We studied the following maternal and neonatal characteristics: maternal geographic origin, last CD4 cell count before delivery, year of birth (divided into 2 calendar periods, 1986-1989 and 1990-1993) , term at birth (defined as premature if delivered after at least 37 weeks of gestation), sex of the child, early evidence of infection (positive DNA polymerase chain reaction or culture result during the first week of life), and infant CD4 cell percentage during the first 3 months of life.
Evaluation of current health status was based on the last questionnaire completed before the age of 18 and included weight, height, and body mass index (BMI) measurements, converted to z scores for age according to French standard growth charts used in clinical practice [17] ; whether the child had ever reached clinical stage C of the Centers for Diseases Control and Prevention (CDC) classification guidelines [18, 19] ; and clinical conditions or events recorded since the previous questionnaire. Immunovirologic status was based on the most recent CD4 cell count and HIV RNA level. Optimal immunologic status was defined as a CD4 cell count 1500 cells/mL, and optimal virologic status was defined as the detection of !50 HIV RNA copies/mL.
We recorded current ART status and history of ART, age at first treatment, age at first HAART (defined as any combination of at least 3 different ART drugs), and composition of the most recent treatment sequence. Living conditions included the vital status of the mother, the adults usually responsible for the adolescent's care, and the adolescent's status in terms of education and employment, including vocational training. School achievement was defined as the highest grade attained, with academic failure defined as having had to repeat 11 grade or dropping out of school.
Statistical analysis. We first compared the maternal and neonatal characteristics for adolescents alive and regularly followed up with those for children lost to follow-up (ie, no data available at the coordinating center for the previous 3 years, taking into account delays for return, monitoring, and entry of data), for children who died before the age of 2 years (mostly rapid progressors), and for those who died at or after 2 years of age. We then described treatment history and current ART sequence, clinical and immunovirologic status, and living conditions at the time of the most recent evaluation for adolescents as a group and for boys and girls separately and used univariate and multivariate analysis to assess their associations with optimal immunovirologic status at the most recent evaluation, defined as a viral load !50 copies/mL and a CD4 cell count 1500 cell/mL. The evolution of growth z scores was assessed using locally weighted scatterplot smoothing, estimated with R software (http://www.r-project.org/). The x 2 test or the Fisher exact test was used for categorical variables, and the Student t test or the Wilcoxon test was used for continuous variables. Logistic regression was used for multivariate analysis. Analyses were conducted using SAS statistical software (version 9.1; SAS Institute).
was used to determine statistical significance. P ! .05
RESULTS
Maternal and Neonatal Characteristics
Among the 2202 mother-child pairs included in the EPF before 1994, 348 infants were infected with HIV-1: 47 (13.5%) of these children died before their second birthday, 58 (17.0%) died at or after the age of 2 years, and 33 (9.5%) were lost to followup ( Table 1) . Most of the deaths occurred before 1996. Early death was more frequent among children born to mothers of African origin and among those with early evidence of HIV infection. These children mostly died of infectious diseases and opportunistic infections. The perinatal characteristics of the 210 adolescents (60%) in regular care were not significantly different from those of the children lost to follow-up, particularly in terms of maternal and neonatal CD4 cell counts, which were lowest in children who died before the age of 2 years. Their median age was 15 years (interquartile range [IQR], 13-16 years) . Half of these adolescents were boys, and 30% were born to mothers from sub-Saharan Africa; 88 reached 18 years old.
Characteristics at Most Recent Evaluation
Living conditions. Most of the adolescents (81.5%) were living with family members, with 65% living with one or both parents ( Table 2 ). The mother was still alive for 54% of adolescents, but 12% lived with other guardians even if the mother was still alive. Approximately one-third of the adolescents whose mothers had died lived with their father, another third lived with other members of the extended family, 8% were adopted, and 20% were in foster care. Data on schooling or occupational status at the most recent evaluation were available for 179 adolescents; their median age was 15 years, which was similar to that of the entire study population. Most (84.3%) were in general schooling, including 15% ( ) who repeated 2 or more grades and 2.2% n p 27 ( ) who dropped out of school; 12.8% were undertaking n p 4 vocational training, and 2.7% required special education. Academic success was not significantly associated with sex or maternal geographic origin but was more frequent when the mother was still alive (73.7%; ) than deceased (58.7%; n p 70 ) ( ). n p 44 P p .05
Treatment history. All but 4 of the adolescents had received ART at some time in their lives. The median age at first ART was 9 months (IQR, 3-19 months) . Treatment began during the first year of life for 39.5% of adolescents, with zidovudine monotherapy as the first-line treatment for 88.3% ( ) n p 182 of ever-treated patients. Overall, 88.6% ( ) of the adn p 186 olescents had been prescribed at least 1 sequence of HAART, initiated at a median age of 7.5 years (range, 3-16 years); 7.1% ( ) had never received 12 nucleoside analogues simuln p 15 taneously, and 1.9% ( ) had received only zidovudine n p 4 monotherapy. Of the patients who had received HAART, 55.6% ( ) had never stopped taking antiretroviral treatment, n p 104 28.3% ( ) had stopped once, and 16% ( ) had n p 53 n p 30 stopped more than once. The median number of HAART sequences was 2.5 (IQR, 1-4). Only 9% ( ) remained on n p 17 their initial HAART regimen.
At the most recent evaluation, 77% of the adolescents were receiving HAART. Treatment combinations included protease inhibitors (PIs) for 75% of patients (mostly boosted PI) and nonnucleoside reverse-transcriptase inhibitors (NNRTIs) for 31%. PIs and NNRTIs were combined for 11% of adolescents.
Sixteen percent of patients had stopped ART, at a median age of 13 years (IQR, 9-14 years). The main reasons for stopping treatment were very poor compliance with HAART (n p ) and slow progression in patients who had received only zi-14 dovudine monotherapy or treatment with 2 nucleoside analogues (
). Tolerance problems were cited as the reason for n p 9 stopping treatment for only 2 adolescents.
Clinical outcomes. CDC stage C clinical conditions had been reached at some point during the lifetime of 19.5% of the adolescents, with no difference in frequency according to sex or ethnicity. Clinical improvements over time were noted for 7 adolescents who presented with HIV-related encephalopathy, although severe motor dysfunction persisted for 3 patients and mild to moderate cognitive impairment continued to be observed for 5 patients. Since the previous evaluation, 15% of the adolescents had presented with an infectious disease. These infections were generally minor, such as bronchitis or upper respiratory tract infection, but 2 cases of varicella-zoster virus infection were observed. At the most recent visit, a small number of clinical symptoms was recorded (enlargement of lymph nodes in 3% and thyroid dysfunction in 1% of the patients). Median weight, height, and BMI z scores for age were 0.11, Ϫ0.02, and 0.02, respectively, with a stable evolution over time from early childhood to age 15 ( Figure 1 ). BMI z scores tended to be slightly lower for boys than for girls ( ). P p .06 Immunovirologic status. Median CD4 cell count and viral load were 557 cells/mL (IQR, 382-861 cells/mL) and 200 copies/mL (IQR, 25-5558 copies/mL), respectively. Low CD4 cell counts (!200/mL) were recorded for 6.6% of patients. Optimal viral control was observed for 43.3% of patients, and optimal immunologic status was observed for 59.1% of patients. Current immunologic status and viral status were strongly correlated; 16.6% of patients with CD4 counts !200 cells/mL and 57.7% of patients with CD4 counts 1500 cells/mL had a viral load of !50 copies/mL (Table 3) .
In logistic regression, optimal immunologic status remained independently associated with younger age at last evaluation and with lower current HIV RNA level. Optimal virological status was independently associated with female sex, with the mother not originating from a sub-Saharan African country, with higher current CD4 cell counts, and with current receipt of HAART (Table 4 ).
DISCUSSION
We have described the living conditions and health outcomes, after a median 15 years of follow-up since birth, among adolescents perinatally infected with HIV in the absence of exposure to perinatal prophylaxis. All of these adolescents were born in France, were identified at birth as having been perinatally exposed to HIV infection, and had similar access to care. This pioneering generation was born at a time when progression to AIDS and early death were common, options for treatment were limited, and the likelihood of survival or of reaching adulthood could not be predicted [20, 21] . Treatment recommendations have changed throughout the lifetime of these patients, with an increase in the treatment options available and improvements in the methods of assessing treatment efficacy and in the management of drug-related adverse events.
Two-thirds of the 348 children born before 1994 survived. Most of these children were treated early, at a median age of 9 months, and 90% began ART before the age of 5 years. HAART has been available for the youngest children of this cohort since they were 3 years old. Treatment with HAART then began at a median age of 7.5 years, and most of the initial NOTE. AOR, adjusted odds ratio; CI, confidence interval; HAART, highly active antiretroviral therapy. a Logistic regression was used for multivariate analysis, adjusting for noncollinear variables found to be associated with undetectable viral load or high CD4 cell count in univariate analysis with in Table 3 . P ! .20 b Date of birth and age at first HAART were collinear with age at last evaluation and therefore were not included in the model. c The factor guardians/caregivers was not included in the model because it was collinear with maternal vital status. d Adjusted for variables included in the model.
HAART combinations included PIs. A small percentage of children (9.5%) were considered lost to follow-up. The median age at the last visit for this group was 6 years, although 8 of these children had been followed up for 110 years. These children had a more favorable perinatal profile and better clinical and biological outcomes, based on available measurements, than did the children in the other 3 groups. The percentage of adolescents who ever presented a CDC class C event (19.5%) was lower than those reported for other cohorts of perinatally infected children (range, 26%-32%) [2, 7, 12] . This may be the result of early access to antiretroviral treatment, before the occurrence of any severe clinical conditions, or a possible selection bias toward sicker children in prevalent cohorts from specialized centers, including perinatally infected children whose infections went undiagnosed during the neonatal period but were diagnosed later because of symptomatic events.
At the most recent evaluation, this adolescent population was fairly healthy, with no new grade C events recorded in the past 6 months. Median z scores for height, weight, and BMI for age were not different from norms for the general population, despite a previous birth cohort study having shown a negative influence of HIV infection on growth patterns, with differences increasing over time [1] . In another retrospective study of 212 children, HAART for a median duration of 71 months was associated with significant increases in mean z scores for weight and height but not for BMI [2] . Our data suggest that diagnosis during the first weeks of life, regular health care, and treatment availability helped perinatally infected children to maintain normal height, weight, and BMI scores up to adolescence. Given that these adolescents survived early childhood despite having limited treatment options, they may also have genetic or other unknown characteristics associated with better initial health status.
Academic achievement was also similar to that for the general population, with a reported academic failure rate of 16.5% for this age group [22] .
Outcomes tended to be better for female subjects, although this difference was not statistically significant. Female subjects had higher anthropometric z scores, higher proportions of optimal virus controllers (49.5% vs 37.5%), and higher proportions of subjects with optimal immunologic status (62.9% vs 55.4%). Optimal viral control has been shown to be significantly correlated with self-reported adherence in a group of adolescents infected sexually or through drug use [23] . A higher median CD4 cell count for girls than for boys has been reported for US cohorts [5] , but another study reported that being female was associated with poorer adherence [24] . Conflicting evidence has been obtained concerning the likelihood of compliance with treatment as a function of sex in adolescents with other chronic conditions [25, 26] . In addition to behavioral issues, there may be alternative physiologic explanations not recorded in the EPF for these differences, such as pharmacokinetic differences in drug clearance [27] .
We observed an independent association between optimal immunologic status and living with adults other than biological parents. In the context of perinatal transmission, the biological parents are necessarily themselves infected or affected by HIV infection. Living with other caregivers was associated with better adherence in other studies [24, 28] . It has been suggested that stressful life events may have a negative influence on the immune status of children [29] . Nevertheless, we found no correlation between maternal vital status and the immunologic status at last evaluation.
Optimal viral control was also associated with the geographic origin of the mother, with current treatment, and with immune status. Overall, 55.7% of the study population had a viral load !500 copies/mL at their most recent evaluation. This figure is below the 80% reported nationally for adult patients treated for at least 6 months [16] . The best results published for pediatric cohorts may reach 60% of patients in the most recent studies (generally on the basis of a threshold of 500 copies/ mL), with the median age of these cohorts often being younger [8, 9, 12, 30] . For adolescents, it is a challenge to maintain optimal treatment adherence [31] ; only 50% of adolescents were reported to have maintained an undetectable viral load 1 year after achieving optimal viral control in a US cohort [32] . In the REACH cohort of adolescents who were behaviorally infected, only 32.5% of adolescents demonstrated sustained virologic suppression [33] . Suboptimal viral suppression was associated with suboptimal ART before HAART and with inadequate adherence.
Factors associated with optimal immunologic response were younger age at the last visit, initiation of HAART at an earlier age, and optimal viral control. Immunologic status was optimal for 59% of the patients, whereas 40% has been reported for adults in France [16] . In the pediatric population, adherence with treatment has been reported to be poorer in older children, with possible effects on CD4 cell counts [24, 34] . Because of the late availability of HAART for this cohort of adolescents born before 1994, age at first HAART and age at last evaluation were closely correlated, so we could not evaluate their independent effect on immunologic status at last evaluation. This study has other limitations: HIV diagnosis during the first 3 days of life was not available for most of this generation, viral load was not routinely measured before 1996, data on viral subtype and adherence were not routinely collected, and systematic assessment of pubertal development started to be done only recently.
In conclusion, the current health status of perinatally infected children followed from birth to adolescence (median duration of follow-up, 15 years) is encouraging, particularly given the limited therapeutic options available during the first few years of these individuals' lives and the specific issues associated with treatment adherence in adolescents with chronic diseases. A new cohort has been initiated to follow up these patients after the age of 18 years, to study the transition to adult care.
